Ani Pharmaceuticals Income Statement (2010-2026) | ANIP

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	48.62M	52.06M	60.93M	64.48M	73.86M	83.82M	94.23M	106.79M	116.55M	131.83M	131.65M	137.43M	138.04M	148.33M	190.57M	197.12M	211.37M	227.81M	247.06M	237.46M
Cost of Revenue (Quarter)	22.31M	24.41M	33.90M	34.27M	35.29M	32.89M	36.33M	37.71M	42.28M	48.10M	53.42M	49.16M	57.70M	63.08M	80.28M	73.04M	74.61M	93.39M	100.27M	93.58M
Gross Profit (Quarter)	26.31M	27.65M	27.03M	30.21M	38.56M	50.93M	57.91M	69.08M	74.26M	83.73M	78.23M	88.27M	80.34M	85.26M	110.29M	124.08M	136.76M	134.42M	146.79M	143.88M
Operating items
Depreciation & Amortization - Total (Quarter)
Research & Development (Quarter)	2.81M	2.46M	3.14M	5.27M	4.17M	7.66M	5.22M	5.92M	7.37M	11.12M	9.87M	10.51M	7.30M	10.13M	16.65M	10.56M	16.54M	12.30M	12.26M	10.60M
Selling, General & Administrative (Quarter)	18.82M	17.18M	30.71M	28.82M	31.96M	30.08M	33.19M	36.47M	38.76M	42.01M	44.46M	48.02M	52.82M	79.08M	69.72M	76.53M	81.77M	76.66M	82.79M	73.66M
Restructuring Costs (Quarter)					2.57M	1.54M	1.20M	1.13M	0.00M
Other Operating Expenses (Quarter)	-8.40M		-0.35M	49.58M	48.08M			53.37M	58.01M	60.75M	70.60M	58.59M	72.75M			83.84M	99.17M	-0.29M	-0.09M	114.32M
Operating Expenses (Quarter)	64.18M	55.62M	84.65M	83.67M	86.77M	88.82M	92.41M	96.89M	104.14M	113.88M	124.93M	117.12M	132.87M	168.85M	194.95M	170.93M	197.48M	191.57M	212.29M	198.57M
Operating Income (Quarter)	-15.55M	-3.56M	-23.72M	-19.20M	-12.91M	-5.00M	1.82M	9.89M	12.40M	17.95M	6.73M	20.31M	5.17M	-20.52M	-4.38M	26.19M	13.89M	36.24M	34.77M	38.89M
EBIT (Quarter)	-15.55M	-3.56M	-23.72M	-19.20M	-12.91M	-5.00M	1.82M	9.89M	12.40M	17.95M	6.73M	20.31M	5.17M	-20.52M	-4.38M	26.19M	13.89M	36.24M	34.77M	38.89M
Non-operating items
Interest & Investment Income (Quarter)	-2.53M	-2.50M	-4.44M	-6.61M	-6.67M	-7.26M	-7.51M	-7.70M	-7.10M	-6.40M	-5.75M	-4.60M	-4.66M	-2.33M	-6.01M	-5.48M	-5.44M	-4.73M	-4.41M	-3.77M
Other Non Operating Income (Quarter)	-0.07M	-1.07M	-2.69M	-0.09M	0.76M	0.04M	-0.04M	-0.03M	-0.05M		-0.03M	-0.03M	-0.09M	-2.54M	-1.38M	0.20M	1.74M		-1.08M	-0.65M
Non Operating Income (Quarter)	-0.07M	-1.07M	-2.69M	-0.09M	0.76M	0.04M	-0.04M	-0.03M	-0.05M	-0.04M	-0.03M	-0.03M	-0.09M	-2.54M	-1.38M	0.20M	1.74M	-0.85M	0.85M	-0.65M
Net income details
EBT (Quarter)	-18.20M	-7.13M	-30.86M	-25.90M	-18.82M	-12.22M	-5.73M	2.17M	5.25M	11.51M	0.95M	25.34M	-2.29M	-31.50M	-13.76M	19.99M	10.53M	33.80M	31.48M	40.22M
Tax Provisions (Quarter)	-4.04M	-2.70M	-6.72M	-5.77M	-3.90M	-3.62M	-1.49M	0.73M	-1.00M	1.60M	-0.21M	7.13M		-7.33M	-3.49M	4.30M	2.00M	7.18M	3.99M	10.73M
Profit After Tax (Quarter)	-14.11M	-4.45M	-24.14M	-20.13M	-14.92M	-8.60M	-4.24M	1.44M	6.25M	9.94M	1.16M	18.21M	-2.29M	-24.17M	-10.28M	15.68M	8.55M	26.62M	27.49M	29.49M
Equity Income (Quarter)												9.65M	-2.71M	1.35M	-2.00M	-0.90M	0.33M	3.14M	0.27M	5.80M
Income from Continuing Operations (Quarter)	-14.15M	-4.43M	-24.14M	-20.13M	-14.92M	-8.60M	-4.24M	1.44M	6.25M	9.91M	1.15M	18.21M	-2.29M	-24.17M	-10.27M	15.69M	8.53M	26.62M	27.49M	29.49M
Consolidated Net Income (Quarter)	-14.15M	-4.43M	-24.14M	-20.13M	-14.92M	-8.60M	-4.24M	1.44M	6.25M	9.91M	1.15M	18.21M	-2.29M	-24.17M	-10.27M	15.69M	8.53M	26.62M	27.49M	29.49M
Income towards Parent Company (Quarter)	-14.15M	-4.43M	-24.14M	-20.13M	-14.92M	-8.60M	-4.24M	1.44M	6.25M	9.91M	1.15M	18.21M	-2.29M	-24.17M	-10.27M	15.69M	8.53M	26.62M	27.49M	29.49M
Preferred Dividend Payments (Quarter)			0.19M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.41M	0.34M
Net Income towards Common Stockholders (Quarter)	-14.11M	-4.45M	-24.33M	-20.54M	-15.33M	-9.01M	-4.65M	1.03M	5.84M	9.53M	0.75M	17.80M	-2.69M	-24.57M	-10.68M	15.28M	8.14M	26.27M	27.49M	29.49M
Additional items
EPS (Basic) (Quarter)	-1.17	-0.37	-1.87	-1.27	-0.94	-0.55	-0.29	0.06	0.30	0.46	0.02	0.84	-0.14	-1.27	-0.55	0.70	0.37	1.19	1.24	1.31
EPS (Weighted Average and Diluted) (Quarter)	-1.17	-0.37	-1.87	-1.27	-0.94	-0.55	-0.29	0.06	0.29	0.45	0.02	0.82	-0.14	-1.27	-0.55	0.69	0.36	1.13	1.17	1.28
Shares Outstanding (Weighted Average) (Quarter)	12.09M	12.11M	12.60M	16.14M	16.27M	16.24M	16.26M	16.39M	17.04M	18.88M	18.00M	19.10M	19.21M	19.40M	19.32M	19.61M	19.72M	19.84M	20.05M	20.91M
Shares Outstanding (Diluted Average) (Quarter)	12.09M	12.07M	12.60M	16.14M	16.20M	16.24M	16.26M	16.53M	17.18M	19.12M	18.19M	19.42M	19.32M	19.40M	19.32M	20.05M	20.31M	20.91M	21.23M	21.54M
EBITDA (Quarter)	-15.55M	-3.56M	-23.72M	-19.20M	-12.91M	-5.00M	1.82M	9.89M	12.40M	17.95M	6.73M	20.31M	5.17M	-20.52M	-4.38M	26.19M	13.89M	36.24M	34.77M	38.89M
Interest Expenses (Quarter)
Tax Rate (Quarter)	22.23%	37.87%	21.77%	22.27%	20.72%	29.64%	25.93%	33.53%	-18.98%	13.90%	-21.86%	28.13%		23.28%	25.36%	21.51%	19.00%	21.25%	12.67%	26.68%

Research Tools

Ani Pharmaceuticals Income Statement (2010-2026) | ANIP

Create an account

Sign In

Reset Password